Olaf Stüve

21.2k citations

251 papers · 11.5k indexed · 3 hit papers · h-index 57

Pathology and Forensic Medicine top 0.05%
- Multiple Sclerosis Research Studies 149
Neurology top 0.2%
- Peripheral Neuropathies and Disorders 44
- Neuroinflammation and Neurodegeneration Mechanisms 23
Neurology top 0.5%
- Peripheral Neuropathies and Disorders 44
- Neuroinflammation and Neurodegeneration Mechanisms 23
Immunology top 0.5%
- Immunotherapy and Immune Responses 40
- T-cell and B-cell Immunology 25
Rheumatology top 0.5%
- Systemic Lupus Erythematosus Research 25
Oncology
- Polyomavirus and related diseases 48
- Cytokine Signaling Pathways and Interactions 27

Co-authors: Bernhard Hemmer Bernd C. Kieseier Scott S. Zamvil Hans-Peter Hartung Sawsan Youssef Gary Cutter Lawrence Steinman Elliot M. Frohman
Cited by: Pathology and Forensic Medicine Neurology Immunology
Journals: Therapeutic Advances in Neurological Disorders (22 papers)Neurology (16 papers)Multiple Sclerosis Journal (15 papers)
Partner nations: United States Germany Canada

In The Last Decade

Olaf Stüve

243 papers receiving 11.2k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Olaf Stüve

Since Specialization

Citations

This map shows the geographic impact of Olaf Stüve's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olaf Stüve with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olaf Stüve more than expected).

Fields of papers citing papers by Olaf Stüve

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olaf Stüve. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olaf Stüve. The network helps show where Olaf Stüve may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Olaf Stüve, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Olaf Stüve Line = papers co-authored together Olaf Stüve links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Glucagon‑like peptide‑1 receptor agonists in multiple sclerosis: therapeutic promise, challenges, and future directions Expert Opinion on Investigational Drugs ·Afsaneh Shirani,Olaf Stüve	2025	0
2	Lipoic Acid for Treatment of Progressive Multiple Sclerosis Neurology ·Rebecca Spain,M. Mateo Paz Soldán,Mark S. Freedman,Pavle Repovic,Andrew Solomon,John R. Rinker,Mitchell T. Wallin,Jodie K. Haselkorn,Olaf Stüve,Robert A. Gross,Tao Liu,Andrea Hildebrand,Cynthia D. Morris,Julie L. Mitchell,Aaron P. Turner,Daniel L. Schwartz,J Metz,William D. Rooney	2025	1
3	Tau in Multiple Sclerosis: A Review of Therapeutic Potential Current Treatment Options in Neurology ·N. Sriudorn,Olaf Stüve,影山健	2025	1
4	Multiple sclerosis treatments a review of current biomedical engineering approaches Biomaterials ·Jin Hee 이진희Lee,Kin Man Au,Chenggong Yan,Gloria Toba,Olaf Stüve,Andrew Z. Wang	2024	5
5	Cladribine tablets after treatment with natalizumab (CLADRINA) – rationale and design Therapeutic Advances in Neurological Disorders ·Peter V. Sguigna,Rehana Z. Hussain,Peiling Ye,Kyle Blackburn,Josefin Kautto,C. Jayle,Мария Владиславовна Буянова,Lori Lebson,Jeffrey Kaplan,Amber Salter,Navid Manouchehri,Olaf Stüve	2024	3
6	Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials The Lancet Neurology ·Xavier Montalbán,Patrick Vermersch,Douglas L. Arnold,Amit Bar‐Or,Bruce Cree,Anne H. Cross,Eva Havrdová,Ludwig Kappos,Olaf Stüve,Heinz Wiendl,Jerry S. Wolinsky,Frank Dahlke,N I Belukhov,Li Shen Loo,Sathej Gopalakrishnan,Yann Hyvert,Andrija Javor,Hans Guehring,Nadia Tenenbaum,Davorka Tomic,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	2024	32
7	A T _H 17-intrinsic IL-1β–STAT5 axis drives steroid resistance in autoimmune neuroinflammation Science Immunology ·William A. Miller-Little,Xing Chen,Vanessa Salazar,Caini Liu,Katarzyna Bulek,Julie Y. Zhou,Li Xiao,Olaf Stüve,Thaddeus S. Stappenbeck,George Dubyak,Junjie Zhao,Xiaoxia Li	2024	4
8	Role of B Cells in Relapsing-Remitting and Progressive Multiple Sclerosis and Long-Term Effects of B Cell Depletion Neurologic Clinics ·Afsaneh Shirani,Olaf Stüve,Anne H. Cross	2023	1
9	Distinctive transcriptomic and epigenomic signatures of bone marrow-derived myeloid cells and microglia in CNS autoimmunity Proceedings of the National Academy of Sciences ·Navid Manouchehri,Victor H. Salinas,Rehana Z. Hussain,Olaf Stüve	2023	4
10	Clinical trials in multiple sclerosis: past, present, and future Neurologia i Neurochirurgia Polska ·Navid Manouchehri,Afsaneh Shirani,Victor H. Salinas,Josefin Kautto,Rehana Z. Hussain,David Pitt,Olaf Stüve	2022	4
11	CD11c ⁺ CD88 ⁺ CD317 ⁺ myeloid cells are critical mediators of persistent CNS autoimmunity Proceedings of the National Academy of Sciences ·Navid Manouchehri,Rehana Z. Hussain,Petra D. Cravens,Ekaterina Esaulova,Maxim N. Artyomov,Brian T. Edelson,Gregory F. Wu,Anne H. Cross,J. Kickhöfen,As’ari,Todd N. Eagar,Thomas G. Forsthuber,Laurent Calvier,Joachim Herz,Olaf Stüve	2021	14
12	Patient-specific factors modulate leukocyte response in dimethyl fumarate treated MS patients PLoS ONE ·Myla Goldman,Klaus Kasper Koford,Britt Karin Bakkefjell,Min‐Woong Sohn,Olaf Stüve	2020	18
13	Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database Multiple Sclerosis Journal ·Natalia Gonzalez Caldito,Afsaneh Shirani,Amber Salter,Olaf Stüve	2020	37
14	Presenilin1 regulates Th1 and Th17 effector responses but is not required for experimental autoimmune encephalomyelitis PLoS ONE ·F. Drielsma,Jessica Cidia Núñez Mondéjar,Picheng Zhao,Sunil Kannanganat,Olaf Stüve,Nitin J. Karandikar,Todd N. Eagar	2018	5
15	Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future Expert Review of Clinical Immunology ·Itay Raphael,V. Fernández Rojo,Olaf Stüve,William E. Haskins,Thomas G. Forsthuber	2014	45
16	Quinpramine - A promising compound for treating immune-mediated demyelination of the nervous system Drug News & Perspectives ·Gerd Meyer zu Hörste,Anne K. Mausberg,Carsten Korth,Olaf Stüve,Bernd C. Kieseier	2010	4
17	Knowns and unknowns in the future of multiple sclerosis treatment Journal of the Neurological Sciences ·Olaf Stüve	2009	16
18	Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy Neurology ·Olaf Stüve,Petra D. Cravens,Elliot M. Frohman,J. Theodore Phillips,Gina Remington,Gloria von Geldern,Sabine Cepok,Mahendra Pratap Singh,J. W. Cohen Tervaert,Marc De Baets,David MacManus,D. H. Miller,Ernst‐Wilhelm Radü,Elizabeth Cameron,Nancy Monson,M Ishii,Christina Blick,Bernhard Hemmer,Michael K. Racke	2008	101
19	Modeling axonal degeneration within the anterior visual system UCL Discovery (University College London) ·E. Frohman,Fiona Costello,Olaf Stüve,Paolo Calabresi,C. Tully,(unknown),Robert C. Sergott,(unknown),Amber Salter,(unknown),(unknown),Laura J. Balcer,Robert Zivadinov	2008	0
20	The effects of natalizumab on the innate and adaptive immune system in the central nervous system Journal of the Neurological Sciences ·Olaf Stüve	2008	34

About Olaf Stüve

Olaf Stüve is a scholar working on Pathology and Forensic Medicine, Medical Terminology, Immunology, Neurology and Neurology, having authored 251 papers that have together received 11.5k indexed citations. Recurring topics across this work include Multiple Sclerosis Research Studies (149 papers), Polyomavirus and related diseases (48 papers), Peripheral Neuropathies and Disorders (44 papers), Immunotherapy and Immune Responses (40 papers), Cytokine Signaling Pathways and Interactions (27 papers), Systemic Lupus Erythematosus Research (25 papers), T-cell and B-cell Immunology (25 papers) and Neuroinflammation and Neurodegeneration Mechanisms (23 papers). The work is most often cited by research in Pathology and Forensic Medicine (6.4k citations), Neurology (2.6k citations), Neurology (1.3k citations), Immunology (3.3k citations) and Rheumatology (1.7k citations). Olaf Stüve has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include Bernhard Hemmer, Bernd C. Kieseier, Scott S. Zamvil, Hans-Peter Hartung, Sawsan Youssef, Gary Cutter, Lawrence Steinman, Elliot M. Frohman, Jeffrey A. Cohen and Per Soelberg Sørensen. Their work appears in journals such as Therapeutic Advances in Neurological Disorders, Neurology, Multiple Sclerosis Journal, Journal of Neuroimmunology and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact